@article{8fa27f4d0eea4646854f982d7cdc179b,
title = "Targeting the gut and tumor microbiota in cancer",
abstract = "Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as shaping cancer immunosurveillance and response to immunotherapy. Our understanding of the complex relationship between different host-intrinsic microorganisms, as well as the multifaceted mechanisms by which they influence health and disease, has grown tremendously—hastening development of novel therapeutic strategies that target the microbiota to improve treatment outcomes in cancer. Accordingly, the evaluation of a patient{\textquoteright}s microbial composition and function and its subsequent targeted modulation represent key elements of future multidisciplinary and precision-medicine approaches. In this Review, we outline the current state of research toward harnessing the microbiome to better prevent and treat cancer.",
author = "Park, {Elizabeth M.} and Manoj Chelvanambi and Neal Bhutiani and Guido Kroemer and Laurence Zitvogel and Wargo, {Jennifer A.}",
note = "Funding Information: The authors thank R. G. Witt, S. Cass, R. Traweek and E. Baruch for their thoughtful input and assistance with preparation of this manuscript. L.Z. and G.K. are supported by Seerave Foundation, the RHU Immunolife, ANR Ileobiome (19-CE15-0029-01), the Ligue contre le Cancer ({\'e}quipe labellis{\'e}e); Agence National de la Recherche (ANR)—Projets blancs; AMMICa (US23/CNRS UMS3655); Association pour la recherche sur le cancer (ARC); Canc{\'e}rop{\^o}le Ile-de-France; Fondation pour la Recherche M{\'e}dicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Universit{\'e} de Paris, ANR-18-IDEX-0001. E.M.P. was supported by the CPRIT Training Award (RP210028). Funding Information: The authors thank R. G. Witt, S. Cass, R. Traweek and E. Baruch for their thoughtful input and assistance with preparation of this manuscript. L.Z. and G.K. are supported by Seerave Foundation, the RHU Immunolife, ANR Ileobiome (19-CE15-0029-01), the Ligue contre le Cancer ({\'e}quipe labellis{\'e}e); Agence National de la Recherche (ANR)—Projets blancs; AMMICa (US23/CNRS UMS3655); Association pour la recherche sur le cancer (ARC); Canc{\'e}rop{\^o}le Ile-de-France; Fondation pour la Recherche M{\'e}dicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Universit{\'e} de Paris, ANR-18-IDEX-0001. E.M.P. was supported by the CPRIT Training Award (RP210028). Publisher Copyright: {\textcopyright} 2022, Springer Nature America, Inc.",
year = "2022",
month = apr,
doi = "10.1038/s41591-022-01779-2",
language = "English (US)",
volume = "28",
pages = "690--703",
journal = "Nature medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "4",
}